BioCentury
ARTICLE | Clinical News

Astex Therapeutics preclinical data

December 8, 2008 8:00 AM UTC

In mice with MM, AT7519 significantly improved overall survival vs. control (40.0 vs. 27.5 days, p=0.0324). The cyclin dependent kinase (CDK) inhibitor also slowed tumor growth vs. control. Data will...